{"name":"Jeil Pharmaceutical Co., Ltd.","slug":"jeil-pharmaceutical-co-ltd","ticker":"","exchange":"","domain":"jeil.com","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"Pharma / Biotech","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":7,"colorKey":"cardiovascular","drugs":[{"name":"Clopirin 1","genericName":"Clopirin 1","slug":"clopirin-1","indication":"Other","status":"marketed"},{"name":"JLP-2002","genericName":"JLP-2002","slug":"jlp-2002","indication":"Other","status":"phase_1"},{"name":"JPI-289 High-dose","genericName":"JPI-289 High-dose","slug":"jpi-289-high-dose","indication":"Other","status":"phase_2"},{"name":"JPI-289 Low-dose","genericName":"JPI-289 Low-dose","slug":"jpi-289-low-dose","indication":"Other","status":"phase_2"},{"name":"JT-003","genericName":"JT-003","slug":"jt-003","indication":"Other","status":"phase_3"},{"name":"Tamsulosin and solifenacin","genericName":"Tamsulosin and solifenacin","slug":"tamsulosin-and-solifenacin","indication":"Other","status":"phase_1"},{"name":"Zeropix","genericName":"Zeropix","slug":"zeropix","indication":"Other","status":"phase_1"}]},{"name":"Cardiovascular","slug":"cardiovascular","revenue":0,"percentOfTotal":0,"drugCount":3,"colorKey":"oncology","drugs":[{"name":"Clopirin 2","genericName":"Clopirin 2","slug":"clopirin-2","indication":"Prevention of atherothrombotic events in patients with acute coronary syndrome","status":"marketed"},{"name":"Metformin + Rosuvastatin","genericName":"Metformin + Rosuvastatin","slug":"metformin-rosuvastatin","indication":"Type 2 diabetes mellitus with dyslipidemia","status":"phase_3"},{"name":"placebo + Rosuvastatin","genericName":"placebo + Rosuvastatin","slug":"placebo-rosuvastatin","indication":"Hypercholesterolemia","status":"phase_3"}]},{"name":"Metabolic","slug":"metabolic","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"immunology","drugs":[{"name":"JLP-2002 A mg","genericName":"JLP-2002 A mg","slug":"jlp-2002-a-mg","indication":"Type 2 diabetes","status":"phase_3"}]}],"pipeline":[{"name":"Clopirin 2","genericName":"Clopirin 2","slug":"clopirin-2","phase":"marketed","mechanism":"Clopirin 2 is an antiplatelet agent that inhibits platelet aggregation to reduce thrombotic events.","indications":["Prevention of atherothrombotic events in patients with acute coronary syndrome","Secondary prevention of myocardial infarction and stroke"],"catalyst":""},{"name":"JLP-2002 A mg","genericName":"JLP-2002 A mg","slug":"jlp-2002-a-mg","phase":"phase_3","mechanism":"JLP-2002 A mg is a small molecule that targets the SGLT2 receptor.","indications":["Type 2 diabetes"],"catalyst":""},{"name":"Clopirin 1","genericName":"Clopirin 1","slug":"clopirin-1","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"JLP-2002","genericName":"JLP-2002","slug":"jlp-2002","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"JPI-289 High-dose","genericName":"JPI-289 High-dose","slug":"jpi-289-high-dose","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"JPI-289 Low-dose","genericName":"JPI-289 Low-dose","slug":"jpi-289-low-dose","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"JT-003","genericName":"JT-003","slug":"jt-003","phase":"phase_3","mechanism":"JT-003 is an investigational therapeutic agent in phase 3 development by Jeil Pharmaceutical, but its specific mechanism of action has not been publicly disclosed.","indications":[],"catalyst":""},{"name":"Metformin + Rosuvastatin","genericName":"Metformin + Rosuvastatin","slug":"metformin-rosuvastatin","phase":"phase_3","mechanism":"This combination reduces blood glucose through metformin's inhibition of hepatic glucose production and increases insulin sensitivity, while rosuvastatin lowers cholesterol by inhibiting HMG-CoA reductase.","indications":["Type 2 diabetes mellitus with dyslipidemia","Cardiovascular risk reduction in patients with diabetes and elevated cholesterol"],"catalyst":""},{"name":"Tamsulosin and solifenacin","genericName":"Tamsulosin and solifenacin","slug":"tamsulosin-and-solifenacin","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Zeropix","genericName":"Zeropix","slug":"zeropix","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"placebo + Rosuvastatin","genericName":"placebo + Rosuvastatin","slug":"placebo-rosuvastatin","phase":"phase_3","mechanism":"Rosuvastatin inhibits HMG-CoA reductase, a key enzyme in the cholesterol biosynthesis pathway.","indications":["Hypercholesterolemia","Prevention of cardiovascular disease"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.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?oc=5","date":"2026-04-02","type":"pipeline","source":"GuruFocus","summary":"Stock List: Research Stocks from Around the World - GuruFocus","headline":"Stock List: Research Stocks from Around the World","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMigAFBVV95cUxQUVM4NElXTlNDa2pEOHhpOV9fXzBVMDRVVVpFUFlsSWoyV3JxWXNqNlZvMlpfM01EVWFzUzQ2aEw3Q3dPbWNUTkVweDhFRnc0bk9CV3JBZTRnR0JtQVY4ZGZWMHAtdGJfbkwtZWZTSUYzVzYwSUY1Y0hCaXNRaWFiONIBlAFBVV95cUxNbnJ3aU12Ym1fMUktNjR2OEdMd2RZR2hEYlRha0lvemJzUzFWSWsyRnJMaE8xOEYxc0lCWnhsTXJiUXdOdEpaenQtUENvU0U5N1BUVG9mS1BDdWw5eldadmgzLXNxZ0liTG9tQzRHQV9mTFJJd2JQOGZjUFdQWlYyY1RTeXk0Wi1zdk0zUG1ZM2NFVkcz?oc=5","date":"2025-10-23","type":"pipeline","source":"Chosunbiz","summary":"Korean pharma firms spin off R&D units to spread risk and speed drug development - CHOSUNBIZ - Chosunbiz","headline":"Korean pharma firms spin off R&D units to spread risk and speed drug development - CHOSUNBIZ","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMixAJBVV95cUxPVEdFQnVwd0NPdlBlZlVUa2p5M0RuRnJlN1l1dHhNMFdicmZoRTZtTWVNeHRZeHJmZnRyanNHT2hQYy1TQWFZT2wzVXdncjF0NWMyNGNYN3hzeVozTGx3aWh4eW9nVGc4RVI0R2o3bE5nVWR3NGlaejNNTkl2dzl3NVRnQ3J1YWFYVXpZYzFrMGgtakdLTUgtUUo5UFNPdE14ZjJwby16VTJoVXlHRDFFVnJuaGJLWUlvOGszbTdFOTZGemhkUjIyaG44bTk2bE5hV001YU9Sa096RWFxRENybTlSX0dVc3VBanVONTl6Y2VqVTMxQ3M0eXByQUxmak5NRV9JZXF5aWkxNlhaYW9tRC01Y0JZcktubGRSdEJlSDEwOUxOQ3RtWkJhOVI0YTM0ZFJxNEx1UHMxV0p4VGRfNGlfNnE?oc=5","date":"2025-09-23","type":"pipeline","source":"PR Newswire","summary":"SGLT2 Inhibitors Market to Expand by 2034 as Companies Leverage Emerging Opportunities in Indications Such as Heart Failure, MASH, Obesity, PCOS, and Others | DelveInsight - PR Newswire","headline":"SGLT2 Inhibitors Market to Expand by 2034 as Companies Leverage Emerging Opportunities in Indications Such as Heart Fail","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiQkFVX3lxTE9teUhfSDh4alRZTGhjdHJ5Wk4zUF82UWU0ckNMUzFHa01UNzZHMmV1QTYtSko2LXlvalNCdFNQekJGdw?oc=5","date":"2025-03-25","type":"pipeline","source":"코메디닷컴","summary":"Jeil Pharmaceutical Names Han Sang-cheol Co-CEO to Launch 3rd-Gen Leadership - 코메디닷컴","headline":"Jeil Pharmaceutical Names Han Sang-cheol Co-CEO to Launch 3rd-Gen Leadership - 코메디닷컴","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimwFBVV95cUxPeE9LM0JZU3pUQVVtOGtuT3FWYkt6aWNwb1lKaFpxX3RDakZlcjNrZWVJSzNIaXNzUk1hU3dTd3RvMFZ5R3Z0NE9aUkpTNDJWUmtYR3ZFYzVneEx6WmM2V3NLTWItWWFuY2hRSV95OHUyT2wxc1hOam11eWJpNzhaX1l1cDF4VVhBSEwzY0ZHcGhWNmRsUDhXVVk5dw?oc=5","date":"2024-12-24","type":"pipeline","source":"BioWorld News","summary":"AI cancer firm Oncocross debuts with $60M IPO on Kosdaq - BioWorld News","headline":"AI cancer firm Oncocross debuts with $60M IPO on Kosdaq","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMinAFBVV95cUxPUHhUSGVxRmYwazgyc3I4SlZkSE9HS0ZxUVExTGRBOGQ1T1l3XzBhaG9Gc19nUVFYTzF0LUxHVlBZR3I2MVBERnJLU2hrN3JpbGhvOGFLYTdLUXhSWjNLalRLemJYa2NDTWNLZlhiOW40dENLNENyMEJIOXA1V2NuU1RVRmNITU9oVERKVUViZmVCaElEX0MwTEtPeWk?oc=5","date":"2024-12-20","type":"pipeline","source":"BioWorld News","summary":"Cancer, GI-focused Onconic shares take off after ₩20B IPO - BioWorld News","headline":"Cancer, GI-focused Onconic shares take off after ₩20B IPO","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiWkFVX3lxTFBUWjkybFNyMGVGeWVWVTVQaXFwcjBzVGFPRHcwV08wQll1MXRNTDNyTkVFaUdGLXktNW8wNXVXWmQzbkpubUZreEQ3Qk9zR0hGZWxvVDlUQmhhUQ?oc=5","date":"2024-11-13","type":"pipeline","source":"Yonhap News Agency","summary":"Jeil Pharm slapped with 300 mln-won fine for providing illegal incentives to doctors - Yonhap News Agency","headline":"Jeil Pharm slapped with 300 mln-won fine for providing illegal incentives to doctors","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMibkFVX3lxTE01amswRENFejJha2VNakh5NVc1ZFA1bndCNk1mX3Z5MWtxUmFNb0RYbmNKWWFxYzhjbVBJSVkwYmRBcEtuNExVdjFxd3ByZUtYN2dWWnZzX3ZYOWcxV19YYWJ5R0lZRXNhYWtqUUt30gFyQVVfeXFMTmIwcFJJZEU0MDlKdko2a1IxcFc2LW02LUpQRkJxN1VCQk42djlpbkd1WDBKWG4tZHB3UFBpVE5jM3BQVHdwZk1jU3g4YURqT3VzUGdneUt4OFNDcmRhdGRtLXJESzJIODFfYk9TTEN6bXpn?oc=5","date":"2024-09-30","type":"pipeline","source":"koreabiomed.com","summary":"Jeil Pharm launches Jaqbo, its 1st in-house drug, in Korea's $1 billion peptic ulcer market - koreabiomed.com","headline":"Jeil Pharm launches Jaqbo, its 1st in-house drug, in Korea's $1 billion peptic ulcer market","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMibkFVX3lxTE04c0NlNzhwdy1WSU1IeHBOR3BiN2U3b19wdGx0ZmpjSkVMY2pOd3gyc3BNdU9KaGJna0N3UUNOTFJBVmNBYlU1UUJLNjY0b0Z0UlJCeDRaLUFZRFl1b3dMZHMwcktzdmZCcWdEUmxR0gFyQVVfeXFMTWtVeGRrSVllb19LZUtMNXFsQnJQMjZ6TmVrNUU2cmJCMG5EX0w0cXh2QnZOVGRtbDBnX2cwMGhnMUdkWk80a2R2aVNXZTYtMlMtUUxuUlpuWHAtSHZ6N3lQTXhpbUhyemthLVEzMmlnTkl3?oc=5","date":"2022-06-07","type":"pipeline","source":"koreabiomed.com","summary":"Amgen, Jeil Pharm to co-promote cholesterol reducer Repatha - koreabiomed.com","headline":"Amgen, Jeil Pharm to co-promote cholesterol reducer Repatha","sentiment":"neutral"}],"patents":[],"drugCount":11,"phaseCounts":{"marketed":2,"phase_3":4,"phase_1":3,"phase_2":2},"enrichmentLevel":2,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}